ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

NCT00615745 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg

Sponsor

Gilead Sciences